शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
KIMSNSEKRISHNA INST OF MED SCI L· Healthcare ServicesHighPositive
Announced Fri, 7 Aug, 2026 · 21:13 IST

KIMS gets NSE/BSE nod for 77 lakh warrants to promoters

Warrants ConvertedFund Raising View source PDFExplain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.4%Reaction day
₹814.90
prior close
₹811.15
announcement price
After-mkt
timing
Nifty Smallcap 250market-0.1%+0.5% vs market
Hospital peers, median of 26sector-0.0%+0.5% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Smallcap 250 and 0.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.1
10m
+0.9
15m
+0.8
30m
+0.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.4-0.1+0.5-0.0+0.5
Next day
-0.2+0.1-0.4-1.3+1.0
2d
-1.8-0.1-1.7-1.5-0.3
3d
-1.6+0.1-1.6-3.2+1.6
4d
-0.7-0.4-0.3-2.4+1.6
5d
-1.7-0.2-1.5-3.3+1.6
1w
-3.2-0.7-2.5-2.4-0.8
15d
-7.6+0.1-7.7-2.4-5.2
1m
-5.0+0.4-5.4-1.5-3.5
2m
-14.1-3.2-10.9-12.0-2.1
3m
—————
UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

KIMS has received in-principle approval from BSE and NSE to issue 77,02,182 warrants to promoters on a preferential basis. Each warrant is fully convertible into one equity share of face value Rs 2 at a price not less than Rs 779. Allottees are Dr Abhinay Bollineni, Mr Adwik Bollineni and Bharas Ventures LLP.

Likely market impact

Promoter commitment strengthens, but conversion will dilute existing shareholders. The Rs 779 price floor signals promoter confidence in valuation.